Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.

Neurology
Jackie BoschHOPE-3 Investigators

Abstract

To assess whether long-term treatment with candesartan/hydrochlorothiazide, rosuvastatin, or their combination can slow cognitive decline in older people at intermediate cardiovascular risk. The Heart Outcomes Prevention Evaluation-3 (HOPE-3) study was a double-blind, randomized, placebo-controlled clinical trial using a 2 × 2 factorial design. Participants without known cardiovascular disease or need for treatment were randomized to candesartan (16 mg) plus hydrochlorothiazide (12.5 mg) or placebo and to rosuvastatin (10 mg) or placebo. Participants who were ≥70 years of age completed the Digit Symbol Substitution Test (DSST), the modified Montreal Cognitive Assessment, and the Trail Making Test Part B at baseline and study end. Cognitive assessments were completed by 2,361 participants from 228 centers in 21 countries. Compared with placebo, candesartan/hydrochlorothiazide reduced systolic blood pressure by 6.0 mm Hg, and rosuvastatin reduced low-density lipoprotein cholesterol by 24.8 mg/dL. Participants were followed up for 5.7 years (median), and 1,626 completed both baseline and study-end assessments. Mean participant age was 74 years (SD ±3.5 years); 59% were women; 45% had hypertension; and 24% had ≥12 years of educatio...Continue Reading

Associated Clinical Trials

May 3, 2007·Salim Yusuf's office

References

Oct 11, 2002·Archives of Internal Medicine·Françoise ForetteUNKNOWN Systolic Hypertension in Europe Investigators
Feb 13, 2003·Archives of Neurology·Chengxuan QiuLaura Fratiglioni
Apr 26, 2005·Aging Clinical and Experimental Research·Yunhwan LeeJeong Lim Kim
Aug 19, 2006·Stroke; a Journal of Cerebral Circulation·Vladimir HachinskiGabrielle G Leblanc
Nov 16, 2006·American Journal of Epidemiology·Cécile Proust-LimaHélène Jacqmin-Gadda
Jan 8, 2008·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Lee AshendorfRobert A Stern
Jul 26, 2008·Annual Review of Psychology·John W Graham
Aug 1, 2008·Lancet·Eric B Larson, Kenneth M Langa
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Bernadette McGuinnessRoger Bullock
Jul 23, 2011·Stroke; a Journal of Cerebral Circulation·Philip B GorelickUNKNOWN American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Counci
Jan 11, 2013·International Journal of Hypertension·Masaki MogiMasatsugu Horiuchi
Apr 5, 2013·Journal of Hypertension·Natacha Levi MarpillatPatrick Maison
Jul 11, 2013·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Katherine A GiffordAngela L Jefferson
Jan 13, 2015·Journal of General Internal Medicine·Brian R OttThomas A Trikalinos
Jan 27, 2015·Current Cardiology Reports·Saurav ChatterjeeDharam J Kumbhani
Mar 25, 2015·Nature Reviews. Neurology·Melinda C PowerRebecca F Gottesman
Jul 8, 2015·Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC·Jérémie M Gauthier, Anne Massicotte
Aug 25, 2015·Current Hypertension Reports·Nisharahmed KheradaClive Rosendorff
Apr 5, 2016·The New England Journal of Medicine·Salim YusufUNKNOWN HOPE-3 Investigators
Apr 5, 2016·The New England Journal of Medicine·Salim YusufUNKNOWN HOPE-3 Investigators
Apr 5, 2016·The New England Journal of Medicine·Eva M LonnUNKNOWN HOPE-3 Investigators
May 20, 2016·JAMA : the Journal of the American Medical Association·Jeff D WilliamsonUNKNOWN SPRINT Research Group
Nov 29, 2016·JAMA Internal Medicine·Kenneth M LangaDavid R Weir
Jun 14, 2017·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Daniel E WeinerUNKNOWN SPRINT Study Research Group

❮ Previous
Next ❯

Citations

Aug 6, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Isabelle BosAnne M Fagan
Jan 23, 2020·Journal of the American Geriatrics Society·Deirdre O'NeillDaniel E Forman
Mar 5, 2020·Stroke; a Journal of Cerebral Circulation·Sonia S AnandUNKNOWN Canadian Alliance for Healthy Hearts and Minds Cohort
Sep 17, 2019·Circulation·Mark A Supiano, Jeff D Williamson
May 20, 2020·JAMA : the Journal of the American Medical Association·Diarmaid HughesMichelle Canavan
May 15, 2019·Journal of Clinical Medicine·Karan GovindpaniAndrea Kwakowsky
May 4, 2021·Journal of Alzheimer's Disease : JAD·Taylor J KrivanekKirk R Daffner
Jun 11, 2021·Clinical Therapeutics·Rachel LitkeJudith Neugroschl
Jun 26, 2021·Journal of the American College of Cardiology·Zhen ZhouUNKNOWN ASPREE Investigator Group
Jul 3, 2021·Nutrients·Milagros RojasEdgar Díaz-Camargo
Aug 1, 2021·British Journal of Anaesthesia·Jessica SpenceP J Devereaux
Dec 7, 2021·European Journal of Preventive Cardiology·Elena OlmastroniManuela Casula
Feb 23, 2020·Current Cardiology Reviews·Christos DamaskosNikolaos Garmpis
Jan 11, 2022·Stroke; a Journal of Cerebral Circulation·Miia KivipeltoKristine Yaffe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.